These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 17037786)

  • 21. Infliximab safety profile and long-term applicability in inflammatory bowel disease: clinical experiences from the eastern side of Europe.
    Molnár T; Farkas K; Nagy F; Szepes Z; Wittmann T
    Aliment Pharmacol Ther; 2010 May; 31(10):1152-3. PubMed ID: 20518754
    [No Abstract]   [Full Text] [Related]  

  • 22. Expanding possibilities in the treatment of patient groups with previously difficult-to-treat patients.
    Dörner T; Burmester GR
    Curr Opin Rheumatol; 2010 May; 22(3):235-6. PubMed ID: 20351494
    [No Abstract]   [Full Text] [Related]  

  • 23. Evaluation of the drug treatment regimens for inflammatory bowel disease.
    Brock EM; Zabihollah M
    Expert Opin Pharmacother; 1999 Nov; 1(1):15-8. PubMed ID: 11249558
    [No Abstract]   [Full Text] [Related]  

  • 24. Immune-mediated reactions to anti-tumor necrosis factors in inflammatory bowel disease.
    Feuerstein JD; Cullen G; Cheifetz AS
    Inflamm Bowel Dis; 2015 May; 21(5):1176-86. PubMed ID: 25581830
    [No Abstract]   [Full Text] [Related]  

  • 25. For pancreatitis in inflammatory bowel disease, treat the bowel.
    Conwell DL; Lashner BA
    Am J Gastroenterol; 1999 Aug; 94(8):2001. PubMed ID: 10445518
    [No Abstract]   [Full Text] [Related]  

  • 26. Novel therapeutic options in the inflammatory bowel disease world.
    Noble A; Baldassano R; Mamula P
    Dig Liver Dis; 2008 Jan; 40(1):22-31. PubMed ID: 17988966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Translating inflammatory bowel disease research into clinical medicine.
    Neurath MF; Finotto S
    Immunity; 2009 Sep; 31(3):357-61. PubMed ID: 19766078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inflammatory bowel disease.
    Hanauer SB; Hommes DW
    Expert Rev Clin Immunol; 2010 Jul; 6(4):499-500. PubMed ID: 20594118
    [No Abstract]   [Full Text] [Related]  

  • 29. [Biological response modifiers in the treatment of immunoinflammatory diseases].
    Skov L; Bendtzen K
    Ugeskr Laeger; 2008 Jun; 170(24):2120-6. PubMed ID: 18565292
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risks and benefits of biologic therapy for IBD.
    Hommes DW
    J Pediatr Gastroenterol Nutr; 2009 Apr; 48 Suppl 2():S52-3. PubMed ID: 19300125
    [No Abstract]   [Full Text] [Related]  

  • 31. [New biological drugs for the treatment of chronic inflammatory diseases].
    Skov L; Hegedüs L; Madsbad S; Bendtzen K
    Ugeskr Laeger; 2008 Jun; 170(24):2162. PubMed ID: 18572482
    [No Abstract]   [Full Text] [Related]  

  • 32. [IL-17/IL-23: a new therapeutic target in inflammatory bowel diseases].
    Malamut G
    Gastroenterol Clin Biol; 2008 Mar; 32(3):354-6. PubMed ID: 18374530
    [No Abstract]   [Full Text] [Related]  

  • 33. Infliximab in ulcerative colitis.
    Aberra FN; Lichtenstein GR
    Gastroenterol Clin North Am; 2006 Dec; 35(4):821-36. PubMed ID: 17129815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Steroids: friends or foes?].
    Gomollón F; Hinojosa J
    Gastroenterol Hepatol; 2008 Sep; 31 Suppl 3():1-2. PubMed ID: 19087856
    [No Abstract]   [Full Text] [Related]  

  • 35. [Practical use of anti-TNF monoclonal antibodies in inflammatory bowel diseases].
    Allez M
    Gastroenterol Clin Biol; 2008 May; 32(5 Pt 1):467-77. PubMed ID: 18448294
    [No Abstract]   [Full Text] [Related]  

  • 36. Sustained response to etanercept after failing infliximab, in a patient with relapsing polychondritis with tracheomalacia.
    Subrahmanyam P; Balakrishnan C; Dasgupta B
    Scand J Rheumatol; 2008; 37(3):239-40. PubMed ID: 18465465
    [No Abstract]   [Full Text] [Related]  

  • 37. Infliximab use in children and adolescents with inflammatory bowel disease.
    de Ridder L; Benninga MA; Taminiau JA; Hommes DW; van Deventer SJ
    J Pediatr Gastroenterol Nutr; 2007 Jul; 45(1):3-14. PubMed ID: 17592358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Focus on mechanisms of inflammation in inflammatory bowel disease sites of inhibition: current and future therapies.
    Van Assche G; Vermeire S; Rutgeerts P
    Gastroenterol Clin North Am; 2006 Dec; 35(4):743-56. PubMed ID: 17129811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Current medical treatment of inflammatory bowel disease].
    Bosques-Padilla F
    Rev Gastroenterol Mex; 2007 Nov; 72 Suppl 2():92-101. PubMed ID: 18277494
    [No Abstract]   [Full Text] [Related]  

  • 40. [Biological drugs in the treatment of immunoinflammatory diseases].
    Nielsen OH; Bendtzen K
    Ugeskr Laeger; 2008 Jun; 170(24):2103. PubMed ID: 18565288
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.